IBRX (ImmunityBio) - Great squeeze potential

IBRX is the perfect setup for an insane short squeeze. We have the perfect squeeze data along with some crazy catalysts, plus it’s actually a great company. Read all of this post and then do your own DD, in my opinion it’s going to explode… Check out what the Chairman and Chief Scientist said 2 days ago to fuel this squeeze on his X account - Dr Pat Soon-Shiong. \# 1. The Trap (Squeeze Metrics) \* \*\*Short Interest:\*\* \\\~40% of float (\\\~120M shares). \* \*\*Days to Cover:\*\* \*\*\\\~10 Days\*\*. If volume spikes, shorts are physically unable to exit fast enough. \* \*\*CTB & FTDs:\*\* Cost to borrow is rising and FTDs (Failure to Delivers) are stacking up. \# 2. The Spark (News Cluster) Shorts usually short the "pop" after news. But they can't right now because the Chairman promised \*\*"multiple press releases"\*\* in a row. \* \*\*Jan 13:\*\* Positive Lung Cancer (NSCLC) Data. \* \*\*Jan 14 (Today):\*\* \*\*Saudi FDA Approval Granted\*\*. \* \*\*Next Up:\*\* Glioblastoma & CAR-NK data is still in the queue. \# 3. The Floor (Fundamentals) This isn't a bankrupt meme stock. \* \*\*Revenue:\*\* Up \*\*424% YoY\*\* ($32.1M) as ANKTIVA sales ramp. \* \*\*Cash:\*\* \*\*$257M\*\* on hand. Bankruptcy risk is off the table. \>\*\*To summarise:\*\* Shorts are trapped in a crowded trade (40% SI) while good news keeps dropping daily. If $3.00 breaks and holds, it’s going to blow up from here.